A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Cefotaxime Injection (Cefotaxime)

First FDA approval2019-08-01
Generic availableNo (brand-only)
Shortage statusActive shortage
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema7 entries indexed · 4 visible
What is Cefotaxime Injection used for?

Cefotaxime Injection is a this drug class medication tracked in Medicare Part D.

Is there a generic for Cefotaxime Injection?

No. Cefotaxime Injection is brand-only with no generic equivalents currently in market.

How much does my plan pay for Cefotaxime Injection?

NADAC pricing data not currently available for this drug.

Is Cefotaxime Injection on the FDA shortage list?

Yes. Cefotaxime Injection is currently listed as an active FDA shortage.

3 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.